Factors influencing platelet recovery after blood cell transplantation in multiple myeloma

Bone Marrow Transplantation

Volumn 20, Issue 5, 1997, Pages 375-380

  Gertz, M A ^a   Lacy, M Q ^a   Inwards, D J ^a   Pineda, A A ^a   Chen, M G ^a   Gastineau, D A ^a   Tefferi, A ^a   Kyle, R A ^a   Litzow, M R ^a  

^a MAYO CLINIC   (United States)

Author keywords

Hematopoietic stem cell; Leukapheresis; Melphalan; Multiple myeloma; Stem cell transplantation

Indexed keywords

CYCLOPHOSPHAMIDE; GRANULOCYTE COLONY STIMULATING FACTOR; MELPHALAN;

ADULT; ARTICLE; FEMALE; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MONONUCLEAR CELL; MULTIPLE MYELOMA; MULTIVARIATE ANALYSIS; NEUTROPHIL; ORAL DRUG ADMINISTRATION; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; STEM CELL TRANSPLANTATION; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTE COUNT; THROMBOCYTE FUNCTION;

EID: 0030755153     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1700897     Document Type: Article

References (42)

1. Barlogie B, Jagannath S, Vesole D, Tricot G. Hematopoietic stem cell autografts in support of myeloablative therapy for multiple myeloma. J Hematother 1994; 3: 149-153.
2. Siena S, Bregni M. Di Nicola M et al. Durability of hematopoietic reconstitution after transplantation of peripheral blood progenitors primed by cancer chemotherapy and rhGM-CSF or rhG-CSF (abstract). Prog Proc Annu Meet Am Soc Clin Oncol 1993; 12: A1547.
3. Watts MJ, Jones HM, Sullivan AM et al. Accessory cells do not contribute to G-CSF or IL-6 production nor to rapid haematological recovery following peripheral blood stem cell transplantation. Br J Haematol 1995; 91: 767-772.
4. Dimopoulos MA, Alexanian R, Przepiorka D et al. Thiotepa, busulfan, and cyclophosphamide: a new preparative regimen for autologous marrow or blood stem cell transplantation in high-risk multiple myeloma. Blood 1993; 82: 2324-2328.
5. Langenmayer I, Weaver C. Buckner CD et al. Engraftment of patients with lymphoid malignancies transplanted with autologous bone marrow, peripheral blood stem cells or both. Bone Marrow Transplant 1995; 15: 241-246.
6. Tarella C, Benedetti G, Caracciolo D et al. Both early and committed haemopoietic progenitors are more frequent in peripheral blood than in bone marrow during mobilization induced by high-dose chemotherapy + G-CSF. Br J Haematol 1995; 91: 535-543.
7. Henry JM, Sykes PJ, Brisco MJ et al. Comparison of myeloma cell contamination of bone marrow and peripheral blood stem cell harvests. Br J Haematol 1996; 92: 614-619.
8. Vescio RA, Han EJ, Schiller GJ et al. Quantitative comparison of multiple myeloma tumor contamination in bone marrow harvest and leukapheresis autografts. Bone Marrow Transplant 1996; 18: 103-110.
9. Berenson JR, Schiller G, Vescio R et al. CD34 peripheral stem cell transplantation in multiple myeloma (abstract). Cancer Invest 1995; 13 (Suppl. 1): 8-9.
10. Haas R, Möhle R, Murea S et al Characterization of peripheral blood progenitor cells mobilized by cytotoxic chemotherapy and recombinant human granulocyte colony-stimulating factor. J Hematother 1994; 3: 323-330.
11. + cells for positive selection in newly diagnosed patients with myeloma. Br J Haematol 1996; 92: 263-268.
12. Tarella C, Boccadoro M, Omede P et al. Role of chemotherapy and GM-CSF on hemopoietic progenitor cell mobilization in multiple myeloma. Bone Marrow Transplant 1993; 11: 271-277.
13. Lamy T, Drenou B, Grulois I et al. Improvement of hematologie recovery after high-dose intensification using peripheral blood progenitor cells (PBPC) mobilized by chemotherapy and GM-CSF. Ann Hematol 1994; 69: 297-302.
14. Femiand JP, Chevret S, Ravaud P et al. High-dose chemoradiotherapy and autologous blood stem cell transplantation in multiple myeloma: results of a phase II trial involving 63 patients. Blood 1993; 82: 2005-2009.
15. Feremans W, Le Moine F, Ravoet C et al. Optimal blood stem cell mobilization using 10 micrograms/kg granulocyte colonystimulating factor (G-CSF) alone for high-dose melphalan intensification in multiple myeloma: an intrapatient controlled study. Am J Hematol 1994; 47: 135-138.
16. Winter JN, Lazarus HM, Rademaker A et al. Phase I/II study of combined granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor administration for the mobilization of hematopoietic progenitor cells. J Clin Oncol 1996; 14: 277-286.
17. 2) and granulocyte colonystimulating factor in patients with multiple myeloma. Bone Marrow Transplant 1996; 17: 691-697.
18. Demuynck H, Delforge M, Verhoef G et al. Comparative study of peripheral blood progenitor cell collection in patients with multiple myeloma after single-dose cyclophosphamide combined with rhGM-CSF or rhG-CSF. Br J Haematol 1995; 90: 384-392.
19. Majolino I, Marcenò R, Buscemi F et al. Mobilization of circulating progenitor cells in multiple myeloma during VCAD therapy with or without rhG-CSF. Haematologica 1995; 80: 108-114.
20. Boiron JM, Marit G, Faberes C et al. Collection of peripheral blood stem cells in multiple myeloma following single high-dose cyclophosphamide with and without recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF). Bone Marrow Transplant 1993; 12: 49-55.
21. Bender JG, To LB, Williams S. Schwartzberg LS. Defining a therapeutic dose of peripheral blood stem cells. J Hematother 1992; 1: 329-341.
22. Scott MA, Ager S, Apperley JF et al. Peripheral blood progenitor cell harvesting in multiple myeloma and malignant lymphoma. Leuk Lymphoma 1995; 19: 479-484.
23. Berenson J, Schiller G, Vescio R et al. Transplantation of CD34-positive peripheral blood progenitor cells following high-dose chemotherapy for patients with advanced multiple myeloma. J Cell Biochem 1995: (Suppl. 21A): 361 (Abstr.).
24. + stem cells. Ann NY Acad Sci 1995; 770: 370-372.
25. Siena S, Bregni M, Brando B et al. Flow cytometry for clinical estimation of circulating hematopoietic progenitors for autologous transplantation in cancer patients. Blood 1991: 77: 400-409.
26. Haas R, Win B, Möhle R et al. Sustained long-term hematopoiesis after myeloablative therapy with peripheral blood progenitor cell support. Blood 1995; 85: 3754-3761.
27. Healy LE, Nirsimloo N, Scott M et al. In vitro proliferation by cells mobilized into the peripheral blood for collection and autologous transplantation. Exp Hematol 1994: 22: 1278-1282.
28. Hirao A, Kawano Y, Takaue Y et al. Engraftment potential of peripheral and cord blood stem cells evaluated by a long-term culture system. Exp Hematol 1994; 22: 521-526.
29. Mittelman M, Lewinski UH, Weiss H et al. Secondary myelodysplastic syndrome in multiple myeloma - a study of nine patients with an attempt to detect myeloma patients at risk. Haematvlogia 1994; 26: 67-74.
30. Walton LA, Yadusky A, Rubinstein L et al. Stage II carcinoma of the ovary: an analysis of survival after comprehensive surgical staging and adjuvant therapy. Gynecol Oncol 1992; 44: 55-60.
31. Samuels BL, Bitran JD. High-dose intravenous melphalan: a review. J Clin Oncol 1995; 13: 1786-1799.
32. Alberts DS, Chang SY, Chen HS et al. Oral melphalan kinetics. Clin Pharmacol Ther 1979; 26: 737-745.
33. Reece PA, Kotasek D, Moms RG et al. The effect of food on oral melphalan absorption. Cancer Chemother Pharmacol 1986; 16: 194-197.
34. Loos U, Musch E, Engel M et al. The pharmacokinetics of melphalan during intermittent therapy of multiple myeloma. EurJ Clin Pharmacol 1988; 35: 187-193.
35. Ehrsson H, Eksborg S, Osterborg A et al. Oral melphalan pharmacokinetics - relation to dose in patients with multiple myeloma. Med Oncol Tumor Pharmacother 1989; 6: 151-154.
36. Down JD, Boudewijn A, Dillingh JH et al. Relationships between ablation of distinct haematopoietic cell subsets and the development of donor bone marrow engraftment following recipient pretreatment with different alkylating drugs. Br J Cancer 1994; 70: 611-616.
37. Lokhorst HM, Sonneveld P, Wijermans PW et al. Intermediate-dose melphalan (IDM) combined with G-CSF (filgrastim) is an effective and safe induction therapy for autologous stem cell transplantation in multiple myeloma. Br J Haetnatol 1996; 92: 44-48.
38. Barbot C, Rice A, Vanès I et al. Quality and functional capacity of the bone marrow microenvironment of autologous blood stem cell transplantation (ABSCT) recipients. Nouv Rev Fr Hematol 1994; 36: 325-331.
39. Tricot G, Jagannath S, Vesole D et al. Peripheral blood stem cell transplants for multiple myeloma: identification of favorable variables for rapid engraftment in 225 patients. Blood 1995; 85: 588-596.
40. Bensinger WI, Rowley SD, Demirer T et al. High-dose therapy followed by autologous hematopoietic stem-cell infusion for patients with multiple myeloma. J Clin Oncol 1996; 14: 1447-1456.
41. Bensinger W. Appelbaum F, Rowley S et al. Factors that influence collection and engraftment of autologous peripheral-blood stem cells. J Clin Oncol 1995; 13: 2547-2555.
42. Prince HM. lmrie K, Sutherland DR et al. Peripheral blood progenitor cell collections in multiple myeloma: predictors and management of inadequate collections. Br J Haematol 1996; 93:142-145.